LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice

Luan, Ning; Cao, Han; Wang, Yunfei; Lin, Kangyang; Liu, Cunbao

doi:10.1016/j.virs.2022.06.002

Cited by 9 publications

(6 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the immunized groups, the AcHERVs immunized groups showed comparatively higher Th1 response than those of the vOka group. When comparing the details between the AcHERVs groups, the group immunized with AcHERV-gE, which encodes VZV-gE (abundant glycoprotein of VZV and a key focus of many studies [ 11 , 12 , 13 ]), exhibited relatively lower values than AcHERV-gE-gB. At this point, this study focused on VZV-gB, which has received less research attention than VZV-gE as an antigen for VZV vaccine development.…”

Section: Discussionmentioning

confidence: 99%

“…This is particularly evident in their ability to elicit robust defenses against VZV, solidifying their prominence in the field [ 10 ]. Given this situation, numerous vaccine candidates with noteworthy features and advantages have been developed and implemented to prevent varicella and HZ [ 11 , 12 , 13 ]. However, it is worthwhile to consider that, based on the characteristics of the VZV, the strategic approach to VZV should not be limited to prevention alone.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions

Lee,

Kim,

Chun

et al. 2024

Vaccines

View full text Add to dashboard Cite

Varicella-zoster virus (VZV) poses lifelong risks, causing varicella and herpes zoster (HZ, shingles). Currently, varicella and HZ vaccines are predominantly live attenuated vaccines or adjuvanted subunit vaccines utilizing VZV glycoprotein E (gE). Here, we propose our vaccine candidates involving a comparative analysis between recombinant baculoviral vector vaccines (AcHERV) and a live attenuated vaccine strain, vOka. AcHERV vaccine candidates were categorized into groups encoding gE only, VZV glycoprotein B (gB) only, or both gE and gB (gE-gB) as AcHERV-gE, AcHERV-gB, and AcHERV-gE-gB, respectively. Humoral immune responses were evaluated by analyzing total IgG, IgG1, IgG2a, and neutralizing antibodies. Cell-mediated immunity (CMI) responses were evaluated by enzyme-linked immunospot (ELISPOT) assay and Th1/Th2/Th17 cytokine profiling. In the mouse model, AcHERV-gE-gB elicited similar or higher total IgG, IgG2a, and neutralizing antibody levels than vOka and showed robust VZV-specific CMI responses. From the perspective of antigens encoded in vaccines and their relationship with CMI response, both AcHERV-gB and AcHERV-gE-gB demonstrated results equal to or superior to AcHERV-gE, encoding only gE. Taken together, these results suggest that AcHERV-gE-gB can be a novel candidate for alleviating risks of live attenuated vaccine-induced latency and effectively preventing varicella during early stages of life while providing strong CMI for effective resistance against HZ and therapeutic potential in later stages of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions

Lee,

Kim,

Chun

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…Shingrix (GSK) is a recombinant subunit vaccine comprising a VZV gE expressed in CHO cells and the liposome-based adjuvant AS01 B . Other work has sought to investigate subunit vaccines against HZ using gE proteins generated from CHO or insect cells formulated with novel adjuvants (Cao et al, 2021;Lee et al, 2020;Luan et al, 2022a, Luan et al, 2022bWang et al, 2021;Wui et al, 2019;Wui et al, 2021). Here, we investigated and showed that the gE protein could be solubly expressed and purified from E. coli, and then formulated as a subunit vaccine candidate with an appropriate adjuvant to elicit not only a robust neutralizing titer but also a strong CMI response.…”

Section: Discussionmentioning

confidence: 99%

Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design

Chen

Sun

Zhang

et al. 2023

Sci. China Life Sci.

View full text Add to dashboard Cite

Varicella-zoster virus (VZV) is a highly infectious agent responsible for both varicella and herpes zoster disease. Despite high efficacy, there remain safety and accessibility concerns with the licensed vaccines. Here, we sought to produce a VZV gE immunogen using an E. coli expression system. We found that the soluble expression and yield of gE protein could be enhanced via C-terminal truncations to the protein, thereby facilitating a robust and scalable purification process for the purpose of vaccine manufacturing. The lead truncated gE (aa 31-358), hereafter referred to as tgE, was a homogenous monomer in solution and showed excellent antigenicity. Finally, we assessed and compared the immunogenicity of tgE with commercial vOka LAV and Shingrix vaccine. We found that aluminum-adjuvanted tgE was immunogenic as compared with vOka LAV. When adjuvanted with AS01 B , a two-dose immunization of tgE showed comparable or better potency in antibody responses and cell-mediated immunity with those of the Shingrix vaccine at the same dosage, especially in terms of the proportion of IFN-γ-expressing CD4 + T cells. In conclusion, this method of E. coli-mediate tgE expression offers a cost-effective and scalable strategy to generate an ideal VZV gE immunogen for the development of both varicella and zoster vaccines. varicella-zoster virus, glycoprotein E, Escherichia coli, vaccine

show abstract

“…Recombinant S-trimer 6P protein at 20 µg/mL was used to stimulate S protein-specific T-cell responses, and the same volume of a solution of PMA+ ionomycin was used as a positive control. Spots were counted with an ELISPOT reader system (Autoimmun Diagnostika GmbH, Strassberg, Germany) after immunoimaging [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice

Luan

Cao

Wang

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

A large amount of real-world data suggests that the emergence of variants of concern (VOCs) has brought new challenges to the fight against SARS-CoV-2 because the immune protection elicited by the existing coronavirus disease 2019 (COVID-19) vaccines was weakened. In response to the VOCs, it is necessary to advocate for the administration of booster vaccine doses to extend the effectiveness of vaccines and enhance neutralization titers. In this study, the immune effects of mRNA vaccines based on the WT (prototypic strain) and omicron (B1.1.529) strains for use as booster vaccines were investigated in mice. It was determined that with two-dose inactivated vaccine priming, boosting with mRNA vaccines could elevate IgG titers, enhance cell-mediated immunity, and provide immune protection against the corresponding variants, but cross-protection against distinct strains was inferior. This study comprehensively describes the differences in the mice boosted with mRNA vaccines based on the WT strain and the omicron strain, a harmful VOC that has resulted in a sharp rise in the number of infections, and reveals the most efficacious vaccination strategy against omicron and future SARS-CoV-2 variants.

show abstract

LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice

Cited by 9 publications

References 55 publications

Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions

Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions

Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design

Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice

Contact Info

Product

Resources

About